CAPR vs SRPT

Capricor Therapeutics is undergoing a critical transition from clinical development to commercialization following the Q3/Q4 2025 FDA approval of CAP-1002 for Duchenne Muscular Dystrophy (DMD). This approval targets a multi-billion dollar market with high unmet needs, particularly for non-ambulatory patients, offering a substantial revenue pathway. The company benefits from regulatory exclusivity ...

Sarepta's 10x growth potential remains tightly linked to the successful, rapid commercialization of Elevidys, its gene therapy for Duchenne Muscular Dystrophy (DMD). While the expanded traditional approval in late 2023 significantly de-risked the regulatory path, market sentiment, as reflected in the market cap, has stabilized slightly from $1.94B to $1.97B since our last analysis 17 days ago, hal...